Harmony Biosciences Holdings (HRMY)
Financial leverage ratio
Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total assets | US$ in thousands | 999,200 | 928,135 | 858,383 | 846,985 | 811,448 | 777,766 | 760,183 | 715,092 | 673,870 | 643,464 | 505,034 | 464,005 | 433,443 | 391,092 | 359,695 |
Total stockholders’ equity | US$ in thousands | 659,155 | 596,804 | 538,583 | 515,394 | 466,992 | 481,332 | 485,172 | 443,041 | 402,838 | 343,884 | 246,533 | 214,503 | 186,507 | 152,018 | 126,551 |
Financial leverage ratio | 1.52 | 1.56 | 1.59 | 1.64 | 1.74 | 1.62 | 1.57 | 1.61 | 1.67 | 1.87 | 2.05 | 2.16 | 2.32 | 2.57 | 2.84 |
December 31, 2024 calculation
Financial leverage ratio = Total assets ÷ Total stockholders’ equity
= $999,200K ÷ $659,155K
= 1.52
The financial leverage ratio of Harmony Biosciences Holdings has shown a decreasing trend over the analyzed period. Starting at 2.84 in June 2021, the ratio has steadily declined to 1.52 by December 2024. This indicates that the company has been reducing its reliance on debt financing in relation to its equity, reflecting a stronger financial position and potentially lower financial risk. The decreasing trend suggests that Harmony Biosciences Holdings has been effectively managing its capital structure and debt levels over time.
Peer comparison
Dec 31, 2024
Company name
Symbol
Financial leverage ratio
Harmony Biosciences Holdings
HRMY
1.52
Abbott Laboratories
ABT
1.90
AbbVie Inc
ABBV
13.00
ACADIA Pharmaceuticals Inc
ACAD
1.69
Alkermes Plc
ALKS
1.40
Amphastar P
AMPH
2.15
ANI Pharmaceuticals Inc
ANIP
2.09
Arcus Biosciences Inc
RCUS
2.37
Biomarin Pharmaceutical Inc
BMRN
1.24
Bristol-Myers Squibb Company
BMY
5.67
Catalyst Pharmaceuticals Inc
CPRX
1.21